Eli Lilly (LLY) Panoramica del titolo
Eli Lilly and Company scopre, sviluppa, produce e commercializza prodotti farmaceutici per uso umano negli Stati Uniti, in Europa, Cina, Giappone e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
LLY Community Fair Values
Create NarrativeSee what 730 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Concorrenti di Eli Lilly and Company
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$989.87 |
| Massimo di 52 settimane | US$1,133.95 |
| Minimo di 52 settimane | US$623.78 |
| Beta | 0.48 |
| Variazione di 1 mese | 5.36% |
| Variazione a 3 mesi | -2.50% |
| Variazione di 1 anno | 32.68% |
| Variazione a 3 anni | 126.70% |
| Variazione a 5 anni | 408.59% |
| Variazione dall'IPO | 35,144.33% |
Notizie e aggiornamenti recenti
Seeking Alpha • May 10
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Summary Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY’s MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead. I maintain my 'strong buy' rating, reinforced by a $2B increase of full-year 2026 revenue guidance and multiple near-term clinical/regulatory milestones expected. Read the full article on Seeking Alpha
Aggiornamento dell'analisi • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.Recent updates
Seeking Alpha • May 10
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Summary Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY’s MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead. I maintain my 'strong buy' rating, reinforced by a $2B increase of full-year 2026 revenue guidance and multiple near-term clinical/regulatory milestones expected. Read the full article on Seeking AlphaAggiornamento dell'analisi • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Aggiornamento dell'analisi • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Aggiornamento dell'analisi • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Nuova analisi • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Aggiornamento dell'analisi • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Aggiornamento dell'analisi • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Aggiornamento dell'analisi • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Aggiornamento dell'analisi • Feb 08
LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward
Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.Articolo di analisi • Feb 07
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...Aggiornamento dell'analisi • Jan 25
LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins
Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.Aggiornamento dell'analisi • Jan 11
LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward
Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.Aggiornamento dell'analisi • Dec 27
LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks
Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.Aggiornamento dell'analisi • Dec 13
LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership
Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.Aggiornamento dell'analisi • Nov 29
LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks
Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.Articolo di analisi • Nov 25
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%
Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Aggiornamento dell'analisi • Nov 21
GLP-1 drugs part of medicare
Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.Aggiornamento dell'analisi • Nov 15
LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks
The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.Articolo di analisi • Nov 07
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...Aggiornamento dell'analisi • Nov 01
LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook
Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.Nuova analisi • Sep 19
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Rendimenti per gli azionisti
| LLY | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 0.1% | -1.5% | 2.6% |
| 1Y | 32.7% | 30.4% | 26.2% |
Ritorno vs Industria: LLY ha superato il US Pharmaceuticals che ha restituito 30.4 % nell'ultimo anno.
Rendimento vs Mercato: LLY ha superato il mercato US che ha restituito 26.2 % nell'ultimo anno.
Volatilità dei prezzi
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: LLY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di LLY è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1876 | 50,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company scopre, sviluppa, produce e commercializza prodotti farmaceutici per uso umano negli Stati Uniti, in Europa, Cina, Giappone e a livello internazionale. L'azienda offre prodotti per la salute cardiometabolica, tra cui Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulina lispro, insulina lispro protamina, insulina lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 per il diabete; Jardiance, Mounjaro e Trulicity per il diabete di tipo 2; e Zepbound per l'obesità. L'azienda fornisce anche prodotti oncologici, come Cyramza per il trattamento di seconda linea del cancro gastrico o dell'adenocarcinoma della giunzione gastro-esofagea; Erbitux per i tumori del colon-retto e della testa e del collo; Inluriyo per il cancro al seno; Jaypirca per la leucemia linfocitica cronica o il linfoma linfocitico di piccole dimensioni; Retevmo per il trattamento del NSCLC metastatico; TYVYT per il linfoma di Hodgkin classico; e Verzenio per il cancro al seno.
Eli Lilly and Company Riepilogo dei fondamenti
| LLY statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$862.31b |
| Utili (TTM) | US$25.28b |
| Ricavi(TTM) | US$72.25b |
34.9x
Rapporto P/E12.2x
Rapporto P/SLLY è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LLY Conto economico (TTM) | |
|---|---|
| Ricavi | US$72.25b |
| Costo del fatturato | US$12.40b |
| Profitto lordo | US$59.85b |
| Altre spese | US$34.57b |
| Utili | US$25.28b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 05, 2026
| Utile per azione (EPS) | 28.35 |
| Margine lordo | 82.83% |
| Margine di profitto netto | 34.99% |
| Rapporto debito/patrimonio netto | 139.0% |
Come si è comportato LLY nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.7%
Rendimento attuale del dividendo22%
Rapporto di remunerazioneLLY paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LLY| Eli Lilly date dei dividendi | |
|---|---|
| Data di stacco del dividendo | May 15 2026 |
| Data di pagamento dei dividendi | Jun 10 2026 |
| Giorni fino al dividendo Ex | 2 days |
| Giorni prima della data di pagamento dei dividendi | 28 days |
LLY paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LLYAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/12 01:32 |
| Prezzo dell'azione a fine giornata | 2026/05/12 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Eli Lilly and Company è coperta da 53 analisti. 27 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |